Skip to main content
. 2020 Jun 8;18:86. doi: 10.1186/s12951-020-00645-y

Fig. 3.

Fig. 3

Immunofluorescence and immunohistochemistry of activated HSCs treated with different drug formulations a; collagen I expression of HSCs treated with different drug formulations b; quantitative analysis of type I collagen in activated HSCs c. (*p < 0.05, **p < 0.01 and ***p < 0.001 vs Control; #p < 0.05 vs G-RGD-NPs)